Market By Drug Class, Distribution Channel, End-user, And Geography | Forecast 2019-2028
As per Triton's research report, the Middle East and African immunosuppressant drugs market is anticipated to upsurge with a CAGR of 5.59% in the forecasting years of 2019-2028.
Report scope can be customized per your requirements. Request For Customization
The countries reviewed in this market are:
•          The UAE
•          Turkey
•          South Africa
•          Saudi Arabia
•          Rest of MEA
More than 500,000 people have pledged organ donation in Turkey, owing to the increasing awareness created by campaigns organized in the National Organ Donation Week. In 2019, doctors in the country performed 4,710 organ transplant procedures across 148 transplantation centers. It holds the record for the largest number of transplants performed in the Middle East region. Living donors are the source of 75% of the donors; whereas, the remaining are harvested from cadavers. The Turkish Transplant Coordinators Association states that, it is among the top three nations in the world in terms of live transplants. 29,000 patients in the country are on the waiting lists for organ replacement. Immunosuppressants are given to patients after they undergo an organ transplant. Thus, the increasing number of transplantations being carried out in the country are raising the demand for immunosuppressant drugs. This is leading to the growth of the studied market in Turkey over the forecast period.
Organ transplant procedures are being carried out in Saudi Arabia since 1979. Initially, these procedures were limited to only renal transplants. Gradually, cardiac transplantation and liver transplantation were introduced. With technological advancements, the country also picked pace, matching the levels of other nations. Currently, there are 12 transplant programs for kidneys, 3 for liver, 2 for lungs, 2 for pancreas, and 1 for cardiac problems throughout the nation. Also, tissue transplants, such as those for cornea, heart valves, and bone, are being offered. Thus, the growing demand for organ transplantation is fueling the growth of the immunosuppressant drugs market in the KSA.
Bristol-Myers Squibb Company's biopharmaceutical segment discovers, develops, licenses, manufactures, markets, distributes and sells innovative medicines to help patients prevail over serious diseases. NULOJIX, AZACTAM, BARACLUDE, COUMADIN, and ELIQUIS are the immunosuppressant drugs manufactured by the company. Bristol-Myers has a notable presence in the Middle East and Africa.
Market By Type, Application, E ..
VIEW REPORT
Market By Device Type, Therape ..
VIEW REPORT
Market By Type, Application, T ..
VIEW REPORT
Market By Technology, Applicat ..
VIEW REPORT
Market By Application, Type, E ..
VIEW REPORT
Market by Therapeutics, Diagno ..
VIEW REPORT
Market by Type, Application, E ..
VIEW REPORT
1. MIDDLE EAST AND AFRICA IMMUNOSUPPRESSANT DRUGS MARKET - SUMMARY
2. INDUSTRY OUTLOOK
2.1. MARKET DEFINITION
2.2. KEY INSIGHTS
2.2.1.  ORGAN TRANSPLANTATION LEADS THE MARKET BY END-USER
2.2.2.  PHARMACEUTICAL INDUSTRY SHOWING GROWTH TRENDS
2.2.3.  IMPACT OF COVID-19 ON TRANSPLANT RECIPIENTS
2.3. EVOLUTION & TRANSITION OF IMMUNOSUPPRESSANT DRUGS
2.4. PORTERS FIVE FORCE ANALYSIS
2.4.1.  THREAT OF NEW ENTRANTS
2.4.2.  THREAT OF SUBSTITUTE
2.4.3.  BARGAINING POWER OF SUPPLIERS
2.4.4.  BARGAINING POWER OF BUYERS
2.4.5.  THREAT OF COMPETITIVE RIVALRY
2.5. MARKET ATTRACTIVENESS INDEX
2.6. VENDOR SCORECARD
2.7. MARKET DRIVERS
2.7.1.  DEMAND FROM ORGAN TRANSPLANTATION
2.7.2.  RISE IN THE NUMBER OF AUTOIMMUNE DISORDERS
2.8. MARKET RESTRAINTS
2.8.1.  SIDE EFFECTS OF IMMUNOSUPPRESSANT DRUGS
2.9. MARKET OPPORTUNITIES
2.9.1.  DEMAND FROM EMERGING ECONOMIES
2.9.2.  EXPORTS OF DRUGS AND MEDICINE WORLDWIDE ON RISE
2.10. MARKET CHALLENGES
2.10.1. LACK OF AWARENESS ABOUT ORGAN DONATION
3. MIDDLE EAST AND AFRICA IMMUNOSUPPRESSANT DRUGS MARKET OUTLOOK – BY DRUG CLASS
3.1. CORTICOSTEROIDS
3.2. MONOCLONAL ANTIBODIES
3.3. CALCINEURIN INHIBITORS
3.4. MTOR INHIBITORS
3.5. OTHERS
4. MIDDLE EAST AND AFRICA IMMUNOSUPPRESSANT DRUGS MARKET OUTLOOK - BY DISTRIBUTION CHANNEL
4.1. HOSPITAL PHARMACIES
4.2. RETAIL PHARMACIES
4.3. ONLINE PHARMACIES
5. MIDDLE EAST AND AFRICA IMMUNOSUPPRESSANT DRUGS MARKET OUTLOOK - BY END-USER
5.1. ORGAN TRANSPLANTATION
5.2. AUTOIMMUNE DISORDERS
5.3. OTHERS
6. MIDDLE EAST AND AFRICA IMMUNOSUPPRESSANT DRUGS MARKET – REGIONAL OUTLOOK
6.1. UNITED ARAB EMIRATES
6.2. TURKEY
6.3. SAUDI ARABIA
6.4. SOUTH AFRICA
6.5. REST OF MIDDLE EAST & AFRICA
7. COMPETITIVE LANDSCAPE
7.1. ABBVIE INC
7.2. ALLERGAN (ACQUIRED BY ABBVIE INC)
7.3. ASTELLAS PHARMA INC
7.4. BRISTOL-MYERS SQUIBB COMPANY
7.5. CIPLA LTD
7.6. DR REDDYS LABORATORIES LTD
7.7. F HOFFMANN-LA ROCHE LTD
7.8. GLAXOSMITHKLINE PLC
7.9. INTAS PHARMACEUTICALS LTD (ACCORD HEALTHCARE)
7.10. JANSSEN PHARMACEUTICALS INC (JOHNSON & JOHNSON SERVICES INC)Â Â Â Â Â Â Â
7.11. MYLAN NV
7.12. NOVARTIS AG
7.13. PFIZER INC
7.14. SANOFI
7.15. VELOXIS PHARMACEUTICALS INC
8. METHODOLOGY & SCOPE
8.1. RESEARCH SCOPE
8.2. SOURCES OF DATA
8.3. RESEARCH METHODOLOGY
TABLE 1: MIDDLE EAST AND AFRICA IMMUNOSUPPRESSANT DRUGS MARKET, BY COUNTRY, 2019-2028 (IN $ MILLION)
TABLE 2: MARKET ATTRACTIVENESS INDEX
TABLE 3: VENDOR SCORECARD
TABLE 4: SIDE-EFFECTS OF IMMUNOSUPPRESSANT DRUGS
TABLE 5: TOP 15 POSITIVE NET EXPORTS COUNTRIES AND NEGATIVE NET EXPORTS FOR DRUGS & MEDICINES COUNTRIES
TABLE 6: MIDDLE EAST AND AFRICA IMMUNOSUPPRESSANT DRUGS MARKET, BY DRUG CLASS, 2019-2028 (IN $ MILLION)
TABLE 7: MIDDLE EAST AND AFRICA IMMUNOSUPPRESSANT DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (IN $ MILLION)
TABLE 8: MIDDLE EAST AND AFRICA IMMUNOSUPPRESSANT DRUGS MARKET, BY END-USER, 2019-2028 (IN $ MILLION)
TABLE 9: MIDDLE EAST AND AFRICA IMMUNOSUPPRESSANT DRUGS MARKET, BY COUNTRY, 2019-2028 (IN $ MILLION)
FIGURE 1: EVOLUTION & TRANSITION OF IMMUNOSUPPRESSANT DRUGS
FIGURE 2: PORTER’S FIVE FORCE ANALYSIS
FIGURE 3: MIDDLE EAST AND AFRICA IMMUNOSUPPRESSANT DRUGS MARKET, BY CORTICOSTEROIDS, 2019-2028 (IN $ MILLION)
FIGURE 4: MIDDLE EAST AND AFRICA IMMUNOSUPPRESSANT DRUGS MARKET, BY MONOCLONAL ANTIBODIES, 2019-2028 (IN $ MILLION)
FIGURE 5: MIDDLE EAST AND AFRICA IMMUNOSUPPRESSANT DRUGS MARKET, BY CALCINEURIN INHIBITORS, 2019-2028 (IN $ MILLION)
FIGURE 6: MIDDLE EAST AND AFRICA IMMUNOSUPPRESSANT DRUGS MARKET, BY MTOR INHIBITORS, 2019-2028 (IN $ MILLION)
FIGURE 7: MIDDLE EAST AND AFRICA IMMUNOSUPPRESSANT DRUGS MARKET, BY OTHERS, 2019-2028 (IN $ MILLION)
FIGURE 8: MIDDLE EAST AND AFRICA IMMUNOSUPPRESSANT DRUGS MARKET, BY HOSPITAL PHARMACIES, 2019-2028 (IN $ MILLION)
FIGURE 9: MIDDLE EAST AND AFRICA IMMUNOSUPPRESSANT DRUGS MARKET, BY RETAIL PHARMACIES, 2019-2028 (IN $ MILLION)
FIGURE 10: MIDDLE EAST AND AFRICA IMMUNOSUPPRESSANT DRUGS MARKET, BY ONLINE PHARMACIES, 2019-2028 (IN $ MILLION)
FIGURE 11: MIDDLE EAST AND AFRICA IMMUNOSUPPRESSANT DRUGS MARKET, BY ORGAN TRANSPLANTATION, 2019-2028 (IN $ MILLION)
FIGURE 12: MIDDLE EAST AND AFRICA IMMUNOSUPPRESSANT DRUGS MARKET, BY AUTOIMMUNE DISORDERS, 2019-2028 (IN $ MILLION)
FIGURE 13: MIDDLE EAST AND AFRICA IMMUNOSUPPRESSANT DRUGS MARKET, BY OTHERS, 2019-2028 (IN $ MILLION)
FIGURE 14: MIDDLE EAST AND AFRICA IMMUNOSUPPRESSANT DRUGS MARKET, REGIONAL OUTLOOK, 2019 & 2028 (IN %)
FIGURE 15: UNITED ARAB EMIRATES IMMUNOSUPPRESSANT DRUGS MARKET, 2019-2028 (IN $ MILLION)
FIGURE 16: TURKEY IMMUNOSUPPRESSANT DRUGS MARKET, 2019-2028 (IN $ MILLION)
FIGURE 17: SAUDI ARABIA IMMUNOSUPPRESSANT DRUGS MARKET, 2019-2028 (IN $ MILLION)
FIGURE 18: SOUTH AFRICA IMMUNOSUPPRESSANT DRUGS MARKET, 2019-2028 (IN $ MILLION)
FIGURE 19: REST OF MIDDLE EAST & AFRICA IMMUNOSUPPRESSANT DRUGS MARKET, 2019-2028 (IN $ MILLION)